Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2011, No. 1


Morales-Briceño H, Cervantes-Arriaga A, Rodríguez-Violante M
Diagnóstico premotor de la enfermedad de Parkinson
Gac Med Mex 2011; 147 (1)

Idioma: Español
Referencias bibliográficas: 82
Paginas: 22-32
Archivo PDF: 123.95 Kb.


Texto completo




RESUMEN

Introducción: La enfermedad de Parkinson (EP) es una trastorno neurodegenerativo caracterizado por bradicinesia, temblor en reposo y rigidez. Patológicamente, la EP se ha definido por la presencia de cuerpos de Lewy, que son resultado de la agregación de a-sinucleína (α-SN). Braak ha propuesto que la enfermedad por agregación de α-SN en la EP comienza en la médula oblongada y progresa predeciblemente alcanzando la sustancia nigra en el mesencéfalo después de afectar el tallo cerebral. Aparte de la sintomatología motora de la enfermedad, los síntomas no motores (SNM) pueden anteceder a la EP, estos incluyen trastornos neuropsiquiátricos, trastornos del sueño y disfunción autonómica. Objetivo: Describir y discutir los SNM y las pruebas diagnósticas con utilidad potencial en el diagnóstico premotor de la EP. Conclusiones: Los síntomas no motores son ahora aceptados como parte integral del espectro de la EP, y existe evidencia que sugiere que la disfunción olfatoria y trastornos del sueño pueden anteceder a los signos motores. La presencia de diversos SNM en conjunto con estudios de imagen tienen el potencial para detectar a pacientes con EP en la fase premotora. Se requieren un número mayor de estudios y en particular diseños de cohorte de sujetos en riesgo.


Palabras clave: Enfermedad de Parkinson, Diagnóstico, Fase premotora.


REFERENCIAS

  1. Hornykiewicz O. The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm. 2006;70:9-15.

  2. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368-76.

  3. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson_s disease: diagnosis and management. Lancet Neurol. 2006;5:235-45.

  4. Tolosa E, Gaig C, Santamaría J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology. 2009;72(Suppl 2):S12-20.

  5. Schapira AH, Agid Y, Barone P, et al. Perspectives on recent advances in the understanding and treatment of Parkinson_s disease. Eur J Neurol. 2009;16:1090-9.

  6. Olanow CW, Perl DP, DeMartino GN, McNaught KS. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 2004;3(8):496-503.

  7. Cook C, Petrucelli L. A critical evaluation of the ubiquitin-proteasome system in Parkinson`s disease. Biochimica et Biophysica Acta. 2009;1792:664-75.

  8. Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197-211.

  9. Braak H, De Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett. 2006;396:67-72.

  10. Lebouvier T, Chaumette T, Damier P, et al. Pathological lesions in colonic biopsies during Parkinson’s disease. Gut. 2008;57:1741-3.

  11. Braak H, Ghebremedhin E, Ru¨b U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318:121-34.

  12. Kaye J, Gage H, Kimber A, Storey L, Trend P. Excess burden of constipation in Parkinson’s disease: a pilot study. Mov Disord. 2006;21: 1270-3.

  13. Orimo S, Uchihara T, Nakamura A, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s disease. Brain. 2008;131:642-50.

  14. Buob A, Winter H, Kindermann M, et al. Parasympathetic but not sympathetic cardiac dysfunction at early stages of Parkinson’s disease. Clin Res Cardiol. 2010. Online Fisrt.

  15. Katzenschlager R, Lees AJ. Olfaction and Parkinson’s syndromes: its role in differential diagnosis. Curr Opin Neurol. 2004;17:417-23.

  16. Gagnon JF, Bedard MA, Fantini MD, et al. REM sleep behavior disorder nd REM sleep without atonia in Parkinson’s disease. Neurology. 2002;59:585-9.

  17. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114:2283-301.

  18. Braak H, Del Tredici K. Cortico-basal ganglia-cortical circuitry in Parkinson’s disease reconsidered. Exp Neurol. 2008;212:226-9.

  19. Weiss F, Koob GF. Drug addiction: functional neurotoxicity of the brain reward systems. Neurotox Res. 2001;3:145-56.

  20. Chateau D, Aron CL. Heterotypic sexual behavior in male rats after lesions in different amygdaloid nuclei. Horm Behav. 1988;22:379-87.

  21. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol. 2008;34:284-95.

  22. Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/ categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008;115:399-407.

  23. Kovacs GG, Milenkovic IJ, Preusser M, Budka H. Nigral burden of alphasynuclein correlates with striatal dopamine deficit. Mov Disord. 2008;23:1608-12.

  24. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745-52.

  25. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.

  26. Newman EJ, Breen K, Patterson J, Hadley DM, Grosset KA, Grosset DG. Mov Disord. 2009;24:2379-85.

  27. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson disease. Arch Neurol. 1993;50:140-8.

  28. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sci. 1991;18:275-8.

  29. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125(part 4):861-70.

  30. Newman EJ, Breen K, Patterson J, Hadley DM, Grosset KA, Grosset DG. Accuracy of Parkinson’s disease diagnosis in 610 general practice patients in the West of Scotland. Mov Disord. 2009;24(16):2379-85.

  31. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33-9.

  32. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations. Mov Disord. 1992;7:2-13.

  33. De Rijk MC, Rocca WA, Anderson DW, et al. A population perspective on diagnostic criteria for Parkinson’s disease. Neurology. 1997;48: 1277-81.

  34. Tanner CM, Gilley DW, Goetz CG. A brief screening questionnaire for parkinsonism. Ann Neurol. 1990;28:267-8.

  35. Duarte J, Claveria LE, De Pedro-Cuesta J, Sempere AP, Coria F, Calne DB. Screening Parkinson’s disease: A validated questionnaire of high specificity and sensitivity. Mov Disord. 1995;10(5):643-9.

  36. Kim JH, Cheong HK, Lee CS, Yi SE, Park KW. The validity and reliability of a screening questionnaire for Parkinson’s disease in a community. J Prev Med Public Health. 2010;43:9-17.

  37. Barbosa MT, Caramelli P, Maia DP, et al. Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambuí study). Mov Disord. 2006;21:800-8.

  38. D’Costa DF, Sheehan LJ, Phillips PA, Moore-Smith B. The Levodopa Test in Parkinson’s Disease. Age Ageing. 1995;24:210-2.

  39. Merello M, Nouzeilles MI, Arce GP, Leiguarda R. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson’s disease diagnosis. Mov Disord. 2002;17:795-8.

  40. Rossi P, Colosimo C, Moro E, Tonali P, Albanese A. Acute challenge with apomorphine and levodopa in parkinsonism. Eur Neurol. 2000;43:95-101.

  41. Ling H, Lees AJ. How can neuroimaging help in the diagnosis of movement disorders? Neuroimaging Clin N Am. 2010;20:111-23.

  42. Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology. 2000;54:697-702.

  43. Hotter A, Esterhammer R, Schocke M, Seppi K. Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism. Mov Disord. 2009;24:S711-20.

  44. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009;72:1378-84.

  45. Péran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson´s disease nigrostriatal signature. Brain. 2010;133: 3423-33.

  46. Walter U, Dressler D, Probst T, et al. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic parkinson disease. Arch Neurol. 2007;64:1635-40.

  47. Woitalla D, Braak H, Tredici KD, et al. Transcranial ultrasound in the differential diagnosis of Parkinson’s disease. Fortschr Neurol Psychiatr. 2010;78:S25-30.

  48. Kägi G, Bhatia KP, Tolosa E. The role od DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81:5-12.

  49. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology. 2001;57:456-62.

  50. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007;22:1581-6.

  51. Gao X, Chen H, Schwarzschild MA, et al.Erectile function and risk of Parkinson’s disease. Am J Epidemiol. 2007;166:1446-50.

  52. Doty RL, Bromley SM, Stern MB. Olfactory testing as an aid in the diagnosis of Parkinson’s disease: development of optimal discrimination criteria. Neurodegeneration. 1995;4(1):93-7.

  53. Haehner A, Boesveldt S, Berendse HW, et al. Prevalence of smell loss in Parkinson’s disease--a multicenter study. Parkinsonism Relat Disord. 2009;15(7):490-4.

  54. Shah M, Deeb J, Fernando M, et al. Abnormality of taste and smell in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(3):232-7.

  55. Ponsen MM, Stoffers D, Booij J, Van Eck-Smit BL, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol. 2004;56(2):173-81.

  56. Berendse HW, Booij J, Francot CM, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson’s disease patients’ relatives with a decreased sense of smell. Ann Neurol. 2001;50(1):34-41.

  57. Marras C, Goldman S, Smith A, et al. Smell identification ability in twin pairs discordant for Parkinson’s disease. Mov Disord. 2005;20(6):687-93.

  58. Dotchin C, Msuya O, Walker R. The use of smell identification tests in the diagnosis of Parkinson’s disease in Brazil. Mov Disord. 2010;25(4):510-1.

  59. Iijima M, Kobayakawa T, Saito S, et al. Smell identification in Japanese Parkinson’s disease patients: using the odor stick identification test for Japanese subjects. Intern Med. 2008;47(21):1887-92.

  60. Silveira-Moriyama L, Carvalho Mde J, Katzenschlager R, et al. The use of smell identification tests in the diagnosis of Parkinson’s disease in Brazil. Mov Disord. 2008;23(16):2328-34.

  61. Boesveldt S, De Muinck Keizer RJ, Knol DL, Wolters E, Berendse HW. Extended testing across, not within, tasks raises diagnostic accuracy of smell testing in Parkinson’s disease. Mov Disord. 2009;24(1):85-90.

  62. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:S2-7.

  63. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson’s disease. Neuroscience. 2008;156(4):830-40.

  64. Van Rooden SM, Heiser WJ, Kok JN, Verbaan D, Van Hilten JJ, Marinus J. The identification of Parkinson’s disease subtypes using cluster analysis: A systematic review. Mov Disord. 2010;25:969-78.

  65. Jankovic J, McDermot M, Carter J, et al. Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990;40:1529-34.

  66. Gagnon JF, Bedard MA, Fantini MD, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease. Neurology. 2002;59:585-9.

  67. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996;46:388-93.

  68. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010;75:494-9.

  69. Stephenson R, Siderowf A, Stern MB. Premotor Parkinson’s disease: clinical features and detection strategies. Mov Disord. 2009;24:S665-70.

  70. Stoessl AJ. Positron emission tomography in premotor Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:S421-4.

  71. Booij J, Knol RJ. SPECT imaging of the dopaminergic system in (premotor) Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:S425-8.

  72. Ponsen MM, Stoffers D, Booij J, Van Eck-mit BLF, Wolters Ech, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson´s disease. Ann Neurol. 2004;56:173-81.

  73. Ponsen MM, Stoffers D, Wolters Ech, Booij J, Bernedse HW. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010;81:396-9.

  74. Berendse HW, Ponsen MM. Diagnosing premotor Parkinson’s disease using a two-step approach combining olfactory testing and DAT SPECT imaging. Parkinsonism Relat Disord. 2009;1553:S26-30.

  75. Stiasny-Kolster K, Doerr Y, Möller JC, et al. Combination of idiopathic REM sleep behaviour disorder and olfactory dysfunction as posible indicator for a-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain. 2005;128:126-37.

  76. Fantini ML, Postuma RB, Montplasir J, Ferini-Strambi L. Olfactory déficit in idiopathic rapid eye movements sleep behavior disorder. Brain Res Bull. 2006;70:386-90.

  77. Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tastch K. Reduced striatal dopamine transporter in idiopathic rapid eye movement sleep behavior disorder. Brain. 2000;123:1155-60.

  78. Berg D, Behnke S, Walter U. Application of transcranial sonography in extrapyramidal disorders: Updated recommendations. Ultraschall Med. 2006;27:12-9.

  79. Prestel J, Schweitzer KJ, Hofer A, Gasser T, Berg D. Predicitive value of transcranial sonography in the diagnoiss of Parkinson’s disease. Mov Disord. 2006;21:1763-5.

  80. Berg D. Ultrasound in the (premotor) diagnosis of Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:S429-33.

  81. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson’s disease: Combining smell tests, trasncranial sonography and SPECT. Mov Disord. 2004;19:1196-202.

  82. Ponsen MM, Stoffers D, Twisk WR, Wolters Ech, Berendse HW. Hyposmia and executive dysfunction as predictors of future Parkinson’s disease: A prospective study. Mov Disord. 2009;24:1060-5.



>Revistas >Gaceta Médica de México >Año2011, No. 1
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019